17:21 , Apr 13, 2018 |  BC Week In Review  |  Financial News

Abpro planning $69M NASDAQ listing

Antibody company Abpro Corp. (Woburn, Mass.) filed on April 12 to raise up to $69 million in an IPO on NASDAQ underwritten by UBS, Wells Fargo, Nomura and Oppenheimer. Abpro's two lead programs, ABP-100 and ABP-201,...
17:20 , Apr 12, 2018 |  BC Extra  |  Financial News

Abpro planning $69M NASDAQ listing

Antibody company Abpro Corp. (Woburn, Mass.) filed to raise up to $69 million in an IPO on NASDAQ underwritten by UBS, Wells Fargo, Nomura and Oppenheimer. Abpro's two lead programs, ABP-100 and ABP-201, are designed to...
20:35 , Feb 23, 2018 |  BC Week In Review  |  Clinical News

Roche reports Phase II data for bispecific DME candidate

Roche (SIX:ROG; OTCQX:RHHBY) reported data from the Phase II BOULEVARD trial to treat diabetic macular edema (DME) showing that once-monthly 6 mg intravitreal RG7716 for 20 weeks met the primary endpoint of improving mean best...
04:08 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

FDA accepts Regeneron's sBLA for 12-week Eylea dosing

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said FDA accepted an sBLA for a quarterly dosing schedule of Eylea aflibercept to treat wet age-related macular degeneration (AMD). Its PDUFA date is Aug. 11, 2018. The drug is already...
21:42 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Regeneron to discontinue nesvacumab/Eylea combo

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said it will discontinue development of a fixed combination therapy comprising nesvacumab (REGN910) plus Eylea aflibercept to treat diabetic macular edema (DME) and wet age-related macular degeneration (AMD) after the combination...
22:10 , Nov 27, 2017 |  BC Extra  |  Clinical News

Regeneron discontinues Eylea/nesvacumab combo

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said it will discontinue development of a fixed combination therapy comprising nesvacumab (REGN910) plus Eylea aflibercept to treat diabetic macular edema (DME) and wet age-related macular degeneration (AMD) after the combination...
23:10 , Oct 6, 2017 |  BioCentury  |  Finance

Coasting on catalysts

While buysiders do not expect any sector-moving milestones in the wake of a catalyst-heavy third quarter, they will have at least 21 Phase III milestones and 23 PDUFA dates on their radar. But the biggest...
19:09 , Jan 18, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers Serum ANG2 levels could help predict responses to anti-CTLA4 or anti-PD-1 mAbs in melanoma patients. In 134 melanoma patients treated with the anti-CTLA4 mAb Yervoy ipilimumab, Yervoy plus a biosimilar of the anti-VEGF...
21:49 , Dec 2, 2016 |  BC Week In Review  |  Company News

Abpro, AstraZeneca deal

The MedImmune LLC unit of AstraZeneca and Abpro partnered to develop MedImmune's preclinical bispecific antibody that targets angiopoietin 2 (ANG2; ANGPT2) and VEGF for multiple undisclosed indications. Abpro will use its DiversImmune platform to further...
07:00 , Jun 9, 2016 |  BC Innovations  |  Translation in Brief

Stopping sepsis

Two teams have uncovered new ways to protect against sepsis in adults and infants by targeting the body's vascular response and inflammatory response, respectively. The findings offer new therapeutic strategies for an indication with few...